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Abstract
BI 2536 is a new anti-mitotic drug that targets polo-like kinase 1 (Plk1) and is currently under clinical development for cancer
therapy. The effect of this drug on cancer cells has been extensively investigated, but information about the effects on
primary dividing cells and differentiated non-dividing cells is scarce. We have investigated the effects of this drug on
primary neonatal rat cardiac fibroblasts and on differentiated cardiomyocytes and explored the possibility to use this drug
to enrich differentiated cell populations in vitro. BI 2536 had a profound effect on cardiac fibroblast proliferation in vitro and
arrested these cells in mitosis with an IC50 of about 43 nM. Similar results were observed with primary human cells (HUVEC,
IC50 =30 nM), whereas the cancer cell line HeLa was more sensitive (IC50 of 9 nM). Further analysis revealed that
prolonged mitotic arrest resulted in cell death for about 40% of cardiac fibroblasts. The remaining cells showed an
interphase morphology with mostly multi- and micro-nucleated nuclei. This indicates that a significant number of primary
fibroblasts are able to escape BI 2536 induced mitotic arrest and apparently become aneuploid. No effects were observed
on cardiomyocytes and hypertrophic response (growth) upon endothelin-1 and phenylephrine stimulation was normal in
the presence of BI 2536. This indicates that BI 2536 has no adverse effects on terminally differentiated cells and still allows
proliferation independent growth induction in these cells. In conclusion, cardiomyocytes could be enriched using BI 2536,
but the formation of aneuploidy in proliferating cells most likely limits this in vitro application and does not allow its use in
putative cell based therapies.
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Introduction
Contamination with proliferating cells is often a serious
problem in cell culture studies investigating differentiated or
quiescent cell populations, since the former can easily overgrow
the cell type of interest. Examples include cardiomyocyte and
neurological cell research, while also in the field of stem cell
differentiation for cell therapies this represents a common
problem. To remove proliferating cells from differentiated cell
populations, nucleotide analogues are often used like bromode-
oxyuridine (BrdU) and arabinoside [1,2], which are incorporated
in the DNA of proliferating cells resulting in DNA damage
checkpoint activation and cell cycle arrest. Since these drugs
affect the genetic code they cannot be used in any subsequent
therapy. Moreover, these analogues are also incorporated in
mitochondrial DNA and can interfere with mitochondrial
biogenesis of the differentiated cell population. Other methods,
like FACS analysis often require specific antibodies and the
throughput is often limited. With the development of more
specific anti-cancer drugs, we decided to investigate the potential
of the Polo-like kinase 1 (PLK1) inhibitor BI 2536 [3,4] as a
potential drug to eliminate proliferating cells from in vitro cultures
containing terminally differentiated cardiomyocytes.
Polo-like kinase 1 (Plk1) is a mitotic kinase, which is highly
expressed in proliferating cells only during the G2 and M phase of
the cell cycle. It has specific roles during mitotic progression,
including centrosome maturation, spindle assembly, chromosome
segregation and cytokinesis [5,6]. Plk1 consist of two domains, a
C-terminal catalytic kinase domain and a N-terminal polo-box-
domain (PBD), which recognizes specific phosphorylated targeting
sequences [7,8] and is essential for its specific localisation and
interaction with some of its substrates [7,9,10]. Micro-injection of
Plk1 antibodies and siRNA based studies targeting Plk1 have
shown the essential role of Plk1 in mitotic progression in cancer
cells [11–15]. These studies revealed that functional interference
with Plk1 resulted in a mitotic arrest with condensed chromo-
somes, monopolar spindles and non-matured centrosomes. Recent
studies with small molecules targeting Plk1, have confirmed these
effects, and moreover revealed late stage mitotic functions for Plk1
[3,16]. Following prolonged mitotic arrest, cell death (apoptosis) is
induced in Plk1-inhibited cancer cells and hence Plk1 has been
proposed to be a promising anti-cancer target [4,17].
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Plk1 in primary cells has only been poorly investigated and
conflicting results have been published. In primary fibroblasts,
Plk1 antibody microinjection was shown to arrest these cells with a
G2-like phenotype, in contrast to the mitotic arrest in cancer cells
[11]. G2-phase functions for Plk1, including recovery from DNA
damage checkpoints, are supported by several studies [18–21].
Nevertheless, the role of Plk1 in G2-M phase transition in
mammalian cells under normal conditions is still under debate [5].
Also siRNA studies showed different results in normal cells, as
compared to cancer cells. In direct comparisons normal cells did
not appear to be affected by Plk1 depletion, whereas cancer cells
arrested in mitosis followed by cell death [12,13]. Together with
the facts that numerous cancer cells show increased Plk1
expression, these results further supported that Plk1 could be a
specific anti-cancer target [17].
BI 2536 is currently the most intensively investigated Plk1
inhibitor [22]. BI 2536 is a small molecule inhibiting Plk1 at sub-
nanomolar concentrations in vitro (0.83 nM) and is equipotently
active against human, mouse and rat Plk1 [4]. It was shown over
1000-fold more selective towards Plk1 as compared to 63 other
kinases and only some activity against the closely related kinases
Plk2 and Plk3 were reported [3]. BI2536 has been tested on
numerous human cancer cell lines in vitro, and tumor Xenograft
models suggested prominent anti-cancer activity [3]. Several phase
I and phase II trials have been performed [22–24], but its potential
as an anti-cancer target still has to be established. The latest phase
II trial study on five different cancer types was rather
disappointing, showing only limited anti-tumor activity [24].
Here we tested the potential in vitro application of this drug by
studyingtheeliminationofproliferatingcellsfromculturescontaining
primary differentiated cells. We used a commonly used system in
cardiac research consisting of partially purified primary differentiated
neonatal cardiomyocytes. We describe the effects of BI 2536 on these
differentiated cells as well as on primary cardiac fibroblasts and show
detrimental effects on primary proliferating cells.
Methods
Reagents and chemicals
Cell culture medium and serum were obtained from Lonza
Benelux B.V. (Breda, The Netherlands) and penicillin-streptomy-
cin and trypsin were from Invitrogen (The Netherlands). Mouse
monoclonal anti-a-actinin antibody EA53 and mouse monoclonal
anti-a-tubulin (B-5-1-2) antibody were from Sigma-Aldrich
Chemie B.V., rabbit polyclonal anti-Troponin (ab9332) was from
Abcam (Cambridge, MA, USA), FITC labelled anti-Phospho-
Histone H3 (Ser10) antibody was from Cell Signaling. Antibody
Dylight 649 labelling kit was from Pierce Biotechnology (Rockford,
IL, USA) BI2536 was purchased from Axon Medchem (Gronin-
gen, The Netherlands) and dissolved in DMSO at a concentration
of 100 mM. L-[4,5-
3H]Leucine (37 MBq/ml; 5,85 TBq/mmol)
was from GE Healthcare Europe (Diemen, Belgium) and Ultima
Gold XR scintillation liquid was from Perkin Elmer (Groningen,
The Netherlands). Unless otherwise stated all chemicals were
purchased at the highest possible grade from Sigma-Aldrich
Chemie B.V. (Zwijndrecht, The Netherlands).
Neonatal rat cardiac myocyte and fibroblast isolation
Neonatal rat ventricle myocytes were isolated from the cardiac
ventricles of 1–3 days old Sprague-Dawley pups. For isolation we
followed a previously described protocol [1,25]. In short, hearts
were removed from the thoracic cavity and placed in a tube
containing cold CBFHH solution (137 mM NaCl, 5.36 mM KCL,
0.81 mM MgSO4, 5.55 mM dextrose,0.44 mM KH2PO4,
0.34 mM Na2HPO4, 20 mM HEPES, pH 7.4.). Ventricles were
separated from other tissue using scissors and cut into several
pieces. Subsequently cardiomyocytes and fibroblasts were de-
tached from the extracellular matrix by repeated incubation in
CBFHH, supplemented with 2 mg/ml trypsin and 20 mg/ml
DNase. Cells were collected by centrifugation and tissue clumps
were removed by filtration. Subsequently, cells were preplated in
cell culture dishes in 50 ml MEM medium with 5% FCS for
45 min. During this period most non-cardiomyocyte cells (mainly
fibroblasts) attached to the dish, whereas cardiomyocytes remained
in solution. The cardiomyocytes were subsequently transferred to
separate tissue culture dishes and allowed to attach. Both
fibroblasts and cardiomyocytes were subsequently cultured in
DMEM medium containing 10% FCS.
All animal studies were conducted in accordance with the NIH
Guide for the Care and Use of Laboratory Animals and approved
by the Committee for Animal Experiments of the University of
Groningen (Approval ID: DEC 5495).
Cell culture
Neonatal rat primary cardiac fibroblasts and cardiomyocytes
and HeLa (S3) were cultured at 37uC under 5% CO2 in DMEM
medium, supplemented with 10% FCS and penicillin-streptomy-
cin (100 IU/ml and 100 mg/ml, respectively). BI was added to a
final concentration of 100 nM, unless otherwise stated. Corre-
sponding control cultures received an equal volume of solvent
(DMSO). Primary human umbilical vein endothelial cells
(HUVEC) were obtained from the Endothelial Cell Facility
(University Medical Center Groningen, The Netherlands). HU-
VEC were isolated from two umbilical cords and prepared as
previously described [26,27]. Cells were cultured on 1% pre-
coated gelatin plates at 37uC under 5% CO2 in RPMI 1640
medium was supplemented with 20% FCS, 2 mmol/l L-
Glutamine, 5 U/ml heparin, 100 IU/ml penicillin, 100 mg/ml
streptomycin and 50 mg/ml endothelial cell growth factor
extracted from bovine brain. HUVEC experiments were con-
ducted with cell passage numbers between 2 and 6.
FACS analysis
For FACS analysis attached cells were detached by trypsin
treatment and collected by centrifugation together with free
floating cells in the medium. After a PBS wash cells were fixed in
4% paraformaldehyde for 10 min at 4uC. Cells were subsequently
washed with PBS and stored at 4uC in PBS until all samples from
one experiment were collected. Subsequently cells were treated
with ice cold PBS + 0.1% tritonX100 for 5 min and washed again
with PBS. Cells were subsequently incubated in 100 ml PBS+1%
BSA containing the indicated antibodies and propridium iodide
(1 mg/ml) for 30 min at room temperature. FITC labeled anti-
Phospho-Histone H3 (Ser10) antibody was used at a 1:200 dilution.
Anti a-actinin antibody was first labelled with DyLight 649,
according to the manufacturer instructions (Pierce Biotechnology,
Rockford, IL, USA). This labelled antibody was then used at a
1:100 dilution. FACS analysis was performed on a FACS calibur
(Becton Dickinson) and data were analysed with WinMDI2.9.
Quantitative Real-Time PCR
Relative expression of ANP, Troponin and Periostin genes was
determined by quantitative PCR (qPCR). Gene expression was
determined by correcting samples for reference gene values
(cyclophilin A), and values were expressed relative to the control
group per experiment. Primer sequences were: Troponin T-1,
cagaagaggttggtcctgatgaa; Troponin T-2, gcaccaagttgggcatgaa;
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Cyclophilin-1, cctcataccagcgacgattc; Cyclophilin-2, atgtggag-
gagtctcacttc.
Microscopy
For cardiomyocytes, coverslips were coated with 1 mg/cm
2
laminin (Millipore) for at least three hours. For fibroblasts non-
coated coverslips were used and HUVEC cells were grown on
coverslips coated with poly-lysine and 1% gelatin. Cells were
grown on coverslips for the indicated time period and subse-
quently washed with PBS and fixed in paraformaldehyde solution
for 10 min at RT. Cells were then permeabilised with ice cold
PBS+0.5% Triton X100 for 5 min and then washed with PBS.
Antibody incubations were performed in PBS+1%BSA for 1 hour
at room temperature. Primary antibodies used were: mouse
monoclonal anti-a-tubulin and rabbit anti-troponin. Secondary
antibodies were: goat anti-mouse Alexa555 (2 mg/ml) and goat
anti-rabbit Alexa488 (2 mg/ml) and nuclei were stained with TO-
PRO3 (Invitrogen-Molecular Probes). Normal overview pictures
and movies were made on a Leica DMIL microscope equipped
with a Leica camera. Confocal images were made on a Leica SP2
AOBS confocal microscope. All images were processed with
ImageJ 1.43 M (NIH, USA) and Adobe Photoshop 7.01.
[
3H]-Leucine incorporation assay
Cells were grown in 12 well plates and subsequently starved for
24 h in DMEM containing starvation medium lacking FCS. As
described previously [28], L-[4,5-
3H]Leucine was added to all
wells and cells were cultured for an additional 20 hours either in
the presence or absence of 10 nM endothelin-1 (ET-1) or 50 mM
phenylephrine (PE). Subsequently, cells were washed twice with
1 ml PBS, followed by an incubation for 1 hour at 4uCi n1m l
cold 5% TCA was. After one wash with TCA solution and one
wash with PBS, proteins were solubilised with 0.5 ml 0.5 M
NaOH for 1 h at RT and transferred to scintillation tubes
containing 5 ml Ultima Gold XR scintillation liquid. The amount
of radioactivity (CPM) was determined by a LS6500 Beckman
Coulter scintillation counter.
Results
BI 2536 treatment of primary cardiomyocyte cultures
Primary cardiomyocytes were isolated from neonatal rat hearts and
were cultured for three days in the presence of serum in order to adapt
to the medium and allow any cardiomyocytes that have not reached
end-stage differentiation to fulfil a last round of division. Subsequently,
cardiomyocyte cultures were treated with the Plk1 inhibitor BI 2536
or were left untreated. As shown in figure 1A, addition of 100 nM BI
2536, a concentration shown to arrest most cell lines maximally [4],
resulted in a small increase in rounded up cells within 24 hours,
indicative for a mitotic arrest. Further analysis by immunofluorescence
microscopy confirmed that these rounded cells were in mitosis and
contained predominantly monopolar spindles with condensed mitotic
chromosomes (Fig. 1B and data not shown). This is similar to what has
been shown for cancer cell lines. Co-staining with troponin-T, a
Figure 2. Effect of BI 2536 on hypertrophy induction in neonatal rat cardiomyocytes. Cardiomyocyte cultures were grown as before with
or without 100 nM BI 2536 and subsequently serum starved in the presence or absence of BI 2536. A. Effect of treatment with the hypertrophy
inducing hormone endothelin-1 on cellular growth ([
3H]-Leucine incorporation) in the presence or absence of BI. [
3H]-Leucine incorporation into
cellular proteins was determined by liquid scintillation counting. Values are relative to the respective non-treated cultures and error bars depict
standard deviations (n=3). B. Analysis of ANP gene expression by real-time PCR in cultures treated with or without ET-1 in the presence or absence of
BI 2536. Levels are corrected for expression of the cyclophilin A housekeeping gene. Error bars depict standard deviations (n=3).
doi:10.1371/journal.pone.0012963.g002
Figure 1. Effect of BI 2536 on neonatal rat cardiomyocytes. Neonatal rat cardiomyocytes were cultured for three days before 100 nM BI 2536, or
DMSO as control, was added. A. Light microscopy pictures of control and24 hours BI 2536 treated cultures.B. Immunofluorescence microscopy pictures
of BI 2536 treated cells stained with anti-troponinT (red) and anti-a-tubulin (green). In the middle a mitotic cell is shown with monopolar spindle devoid
of troponin T staining. Scale bar is 10 mM. C. FACS analysis of 24 h treated and untreated cells stained with anti-a-actinin and anti-Phospho-Histone H3.
Four regions are selected and marked as follow: C-I= cardiomyocytes in interphase, C-M = cardiomyocytes in mitosis, F-I= fibroblasts in interphase, F-
M = fibroblasts in mitosis. D. Quantification of FACS profiles of control and 24 h BI 2536 (BI) treated cells stained like in C. Dark grey bars indicate the
percentage interphase cells and light grey bars indicate the percentage mitotic cells. CM= cardiomyocyte, Fibro= fibroblast.
doi:10.1371/journal.pone.0012963.g001
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cardiomyocytes and cardiomyocytes all showed normal interphase
m o r p h o l o g y( F i g .1 B ) .T of u r t h e rconfirm this, FACS analysis was
performed using phospho-Histone H3 as a mitotic marker and a -
actinin as a cardiomyocyte marker. In the control culture almost all
cells were phospho-Histone H3 negative, and hence in interphase
figure 1C–D. Moreover, a significant proportion of cells were alpha-
actinin negative, indicating the presence of non-cardiomyocytes. This
relative high level of these cells is most likely a result of the three days
cultivation without inhibitors. Importantly, after 24 hours BI 2536
treatment a significant portion of cells became phospho-Histone H3
positive and these were almost all a-actinin negative (Fig. 1C–D). This
shows that cardiomyocytes were not sensitive to BI 2536 and that
predominantly the non-cardiomyocyte cells were targeted by BI 2536.
BI 2536 does not affect cardiomyocyte function and
cellular growth (hypertrophy)
Next we addressed if cardiomyocyte function could be affected
by BI 2536. We first examined the beating frequency of these cells
by video imaging. As shown in the supplemental videos beating
frequency in BI 2536 treated cultures (File S1) was similar to
control cultures (File S2). Also beta-adrenergic stimulation by
isoproteronol was still normal in BI 2536 treated cells (data not
shown). Even after two weeks incubation cardiomyocyte beating
was still evident, indicating that BI 2536 does not show apparent
interference with this major cardiomyocyte function.
Primary neonatal cardiomyocyte cultures are predominantly
used as a model for cardiac hypertrophy. After two days culture of
cardiomyocytes cells were treated with or without BI 2536 for 24 h
followed with a similar incubation in starvation medium.
Thereafter cells were treated with the hypertrophy inducing
stimuli endothelin-1 (ET-1) or phenylephrine (PE) in the presence
of [
3H]Leucine. After 24 hours cells were harvested and the
amount of [
3H]Leucine incorporation into protein was deter-
mined. As shown in figure 2A ET-1 strongly increased
[
3H]Leucine incorporation in cardiomyocytes and similar results
were observed with PE (data not shown). This effect was even
stronger in the presence of BI 2536, indicating that BI 2536 did
not interfere with growth induction. The apparent stronger effect
Figure 3. BI 2536 reduces fibroblast numbers in cardiomyocyte cultures. Cardiomyocyte cultures were grown as before with or without
100 nM BI 2536. A) The percentage cardiomyocytes and cardiac fibroblasts were determined by FACS analysis, using anti- a-actinin staining. Before
harvest mitotic cells were removed by shake off. Light gray bars indicate fibroblasts, dark grey bars show the percentage cardiomyocytes. B After
24 hour treatment RNA was isolated from cells and real time PCR was performed with primers against cardiac troponin T to determine the expression
level of this cardiomyocyte specific gene, providing an indirect measure for the number of cardiomyocytes. Error bars depict standard deviations
(n=3). C. Same as in B, but with primers against periostin, a marker for cardiac fibroblasts.
doi:10.1371/journal.pone.0012963.g003
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in these cultures (see also below and figure 3). To further
corroborate this we also investigated ANP gene expression, which
is a marker for the hypertrophic response and is expressed in
cardiomyocytes only. As shown in figure 2B, ANP expression was
similarly up regulated in ET-1 treated cell cultures with and
without BI 2536. Together, these results show that BI 2536 does
not affect proliferation independent growth inducing responses.
Not all non-cardiomyocytes can be removed by BI 2536
treatment
The above results showed no apparent interference of
cardiomyocytes function in the presence of BI 2536. Next we
wanted to know if proliferating cells (.95% fibroblasts) in these
cultures could be reduced by BI 2536 treatment. We included a
mitotic shake-off to remove most mitotic cells before FACS
analysis. As shown in figure 3A, 24 hours BI treatment could
already significantly reduce fibroblasts, resulting in a concomitant
relative increase in the percentage of cardiomyocytes. This relative
increase was further confirmed by the increase of troponin T
expression, a cardiomyocytes specific marker, in these cultures
(Figure 3B). Conversely expression of the fibroblast marker
periostin decreased in these cultures. This further confirmed that
only non-cardiomyocytes, predominantly fibroblasts, were affected
in these cultures. As shown in figure 3A, prolonged incubation
with BI could further lower the percentage of fibroblasts in these
cultures. Nevertheless, even after 72 hours, still about 20% non-
cardiomyocytes were present as determined by FACS analysis.
This is surprising since these cells can perform 2–3 rounds of cell
division within this time period (cycling time 28 h). This suggests
that not all proliferating cells are properly targeted by BI 2536.
BI 2536 induces mitotic arrest of primary cardiac
fibroblasts
The contaminating cells in our cardiomyocyte cultures consisted
predominantly of cardiac fibroblasts (.95%, data not shown).
These cells are easily enriched by preplating and were subse-
quently used to test the effect of BI 2536 specifically on these
primary proliferating cells. Since not all cells appeared to arrest
with BI 2536 (figure 3A), we analysed the concentration
dependency. Using FACS analysis we determined the number of
cells that arrested within 24 hours treatment with different BI
2536 concentrations. This dose response curve revealed that
primary fibroblast arrest was maximal at a dose of 100 nM and the
IC50 value was approximately 43 nM (Fig. 4A). Not all cells did,
however, arrest and a maximum of approximately 50% was
observed at concentration of 100 nM and higher. The arrest of
cardiac fibroblasts after 24 hours treatment with 100 nM BI 2536
was also clearly evident by the strong increase of rounded up cells
(Fig. 4B). Immunofluorescence microscopy confirmed the typical
monopolar arrest of these cells, in contrast to the mostly bipolar
mitotic cells in the control culture (Fig. 4B). With HeLa cells an
IC50 of only 9 nM was observed (Fig. 4A), confirming previous
results with these cells, and the maximal percentage of arrested
cells was around 63%. At these low concentrations no effects were
observed on neonatal rat cardiac fibroblast, showing that these
cells are less sensitive. We also tested human primary HUVEC
cells which arrested with an (IC50 of 30 nM), indicating that
different cell types show different sensitivities.
BI 2536 temporarily arrests primary cardiac fibroblasts
To further corroborate the effect on primary fibroblasts, we
also analysed the effect of BI 2536 in time. As shown in
figure 5A, 24 hours after treatment with BI2536 a clear mitotic
population (phospho-Histone H3 positive) is present, which is
absent in the control culture. In time, however, this population
is diminishing, and a population of dead, low propidium iodide
stained cells became apparent. Prolonged culturing of control
cells did only provide a small increase in dead cells.
Quantification of FACS experiments (Fig. 5B) revealed that
after 24 hours about 41,5% of the cells were in mitosis and that
6,5% cells were dead. After 72 hours this has almost inverted
with an average of 4,3% mitotic cells and 40,1% dead cells.
Importantly, at this stage still about 55,1% of interphase cells
were present. These cells were investigated by immunofluores-
cence microscopy and it turned out that more than 90% of these
cells had multi- or micro-nucleated nuclei (Fig. 5C), a clear sign
of aberrant mitotic progression. We did not observe this micro-
nucleation in cardiomyocytes t r e a t e dw i t hB I2 5 3 6( d a t an o t
shown), which further supports that this only occurred in
proliferating cells, most likely due to an escape of the BI 2536
induced mitotic arrest. This also clarifies why BI 2536 treatment
Figure 4. Effect of BI 2536 on rat cardiac fibroblasts. Rat cardiac
fibroblasts were cultured for two days before the indicated doses of BI
2536 or DMSO as a control were added. HeLa cells were cultured under
identical conditions. A. Dose response curve of primary cardiac
fibroblasts and HeLa cells. Cells were cultured for 24 hours with BI
2536 and subsequently fixed and stained with anti-Phospho-Histone
H3, as a mitotic marker, and then quantified by FACS analysis. Closed
circles, HeLa cells; open circles, cardiac fibroblasts. B. Light microcopy
pictures of control and 24 h BI 2536 treated cardiac fibroblast cultures
C. Immunofluorescence microscopy pictures of same cells as in B, but
stained with anti-a-tubulin (green) and the DNA stain TOPRO-3 (blue).
Scale bar is 10 mM.
doi:10.1371/journal.pone.0012963.g004
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cardiomyocyte cultures.
Discussion
In this paper we describe the effect of BI 2536 on primary
cardiac fibroblasts and cardiomyocytes. We showed herein that BI
2536 does not generate adverse effects in cardiomyocytes, but does
profoundly affect primary fibroblast. In particular, fibroblasts were
arrested in mitosis with monopolar spindles and died upon
prolonged arrest. Nevertheless part of the cells escaped mitotic
arrest, as was evident from the large number of multi- and micro-
nucleated cells. Since aneuploidy is a hallmark of most solid
cancers, this could be a potential concern for its use and will limit
the potential of Plk1 inhibitors for enrichment of differentiated
cells for cell therapy. As far as we know, this is the first analysis of
the effects of BI 2536 on both primary and differentiated cells.
BI 2536 did not appear to affect the function of differentiated
cells, as tested here using neonatal cardiomyocytes. No apparent
morphological changes were observed and cardiomyocyte beating
continued in the presence of BI 2536. Even after 4 weeks
incubation with BI 2536 these cells continued normal beating
(data not shown). Despite the fact that these cells cannot proliferate
anymore, cardiomyocytes can still increase in size, and cardiomy-
ocyte hypertrophy is one of the hallmarks of heart failure [29,30].
We therefore also evaluated the effect of BI 2536 on the
hypertrophic response to phenylephrine and endothelin-1 in vitro.
As shown here cardiomyocyte hypertrophy could be induced in
the presence of BI 2536, and even appeared more pronounced
than in the absence of BI 2536. The latter was most likely due to
the reduction in fibroblasts in these BI 2536 treated cultures,
resulting in lower background values. Thus, BI 2536 specifically
blocks proliferation, but does not seem to affect proliferation-
independent hypertrophic cell growth of cardiomyocytes.
Our results with BI 2536 showed a clear mitotic arrest of primary
rat fibroblast with monopolar spindles, which is similar to the
observed arrest of cancer cells. This is in contrast to anti-Plk1
microinjection study in human fibroblasts, which showed predom-
inantly a G2 phase-like arrest phenotype in primary cells, despite a
clear mitotic arrest in cancer (HeLa) cells [11]. Although we cannot
exclude a possible G2 delay in these cells, the major phenotype is
mitotic arrest. A similar observation was made with primary human
(HUVEC) cells, indicating that this is not due to species differences
(data not shown). PLK1 siRNA based studies have suggested that
Plk1 depletion did not affect normal cells or was much less effective
in normal cells, as compared to cancer cells [12,13]. Although
higher concentrations of BI2536 were required to arrest primary rat
fibroblasts as compared to HeLa cels, we observed a clear mitotic
arrest indicating that also in normal cells Plk1 is essential for proper
mitotic progression. The absence of a mitotic phenotype with
siRNA studies suggests, therefore, that depletion was not sufficient
to generate this phenotype in normal cells.
Like in cancer cells arrested by Plk1 depletion or inhibition, we
also observed cell death in primary cells following the mitotic
arrest. In addition, however, we observed multi- and micro-
nucleated cells in primary fibroblast populations treated with
BI2536. After 72 hours even more than 90% of the present
interphase fibroblasts showed this multi- and micro-nucleation
phenotype. This phenotype is a clear sign of abnormal mitotic
progression, indicating that a substantial number of primary
fibroblasts escaped the mitotic arrest. This effect has not been
reported for cancer cells treated with BI 2536 [4]. This is
surprising since it is often thought that, in contrast to normal cells,
cancer cells might have a partially impaired mitotic checkpoint,
explaining chromosome instability in the latter [31]. Thus, it
appears that cancer cells die more efficiently upon Plk1 inhibition,
as compared to normal cells. The latter is in line with a recent
study describing the effects of microtubule drugs on cancer and
normal cells [32]. In this paper, the authors described that cancer
cells are more susceptible to cell death upon mitotic arrest by the
microtubule stabilizing agent taxol, as compared to normal cells.
Our results suggest that this might be similar for Plk1 mediated
mitotic arrests, suggesting that this is a general spindle checkpoint
associated phenomenon. Although this is beneficial for the
elimination of cancer cells, it begs the question what will happen
with normal cells that have become aneuploid as a result of BI
2536 treatment. Since aneuploidy is a hallmark of most solid
tumors [33] this could be a concern.
Altogether, our results show that Plk1 inhibition by BI 2536
treatmenthasnoobviouseffectsondifferentiated cardiomyocytes.It
also, showsthat whereasBI2536 caninhibit proliferationitdoes not
affect proliferation independent cell growth. Plk1 inhibition by BI
2536 resulted in mitotic arrest of primary fibroblast followed either
by cell death or checkpoint slippage and aneuploidy. The latter will
hamper the potential use of Plk1 inhibitors for the depletion of
proliferating cells from differentiated cell cultures for cell therapy
and might be a concern in general. Nevertheless, as shown here, it
could be useful in cell cultures for in vitro applications.
Supporting Information
File S1 Cardiomyocytes were treated with BI2536 and then
recorded by video imaging. Note the presence of rounded mitotic
fibroblast, which are absent in the control culture (File S2).
Found at: doi:10.1371/journal.pone.0012963.s001 (9.82 MB
MOV)
File S2 Video imaging of a control culture of cardiomyocytes
(without treatment).
Found at: doi:10.1371/journal.pone.0012963.s002 (8.53 MB
MOV)
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Figure 5. BI 2536 temporarily arrests cardiac fibroblasts. Rat cardiac fibroblasts were cultured for two days before 100 nM BI 2536 or DMSO as
control were added. Cells were subsequently analysed at different time points. A. FACS analysis of cells stained with anti-Phospho-Histone H3 and
propidium iodide. In the upper panel the control cells are shown and in the lower panel the BI2536 treated cells. The different regions are marked as
follow: I is interphase, M is mitosis and D denotes dead cells. B. Quantification of FACS profiles, as shown in A (n=3). Dark grey bar depict interphase
cells, light grey bar depicts mitotic cells and white bar depicts dead cells. C. Immunofluorescence pictures of remaining interphase cells after 72 hours
culture in the presence or absence of BI 2536. Cells were stained with anti-a-tubulin (green) and the DNA stain TOPRO-3 (blue). Control cells are
shown in the upper panel. Scale bar is 10 mM.
doi:10.1371/journal.pone.0012963.g005
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